Nivolumab+relatlimab (Opdualag® ). HTA ID: 24009

Assessment Status Rapid Review Complete
HTA ID 24009
Drug Nivolumab+relatlimab
Brand Opdualag®
Indication Nivolumab+relatlimab (Opdualag® ) is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%.
Assessment Process
Rapid review commissioned 05/03/2024
Rapid review completed 16/04/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab+relatlimab compared with the current standard of care.